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ABSTRACT 
Previous studies among patients with atrial fibrillation showed that a history of heart failure (HF) could 
negatively impact anticoagulation quality, as measured by the average time in therapeutic range (TTR). 
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Whether additional markers of HF severity are associated with TTR has not been investigated 
thoroughly. We aimed to examine the potential role of HF severity in the quality of warfarin control 
among patients with HF with reduced ejection fraction. Data from the Warfarin vs. Aspirin in Reduced 
Cardiac Ejection Fraction Trial (WARCEF) were used to investigate the association between TTR and 
HF severity. Multivariable logistic regression models were used to examine the association of markers 
of HF severity, including New York Heart Association (NYHA) class, Minnesota Living with Heart 
Failure (MLWHF) score and frequency of HF hospitalization, with TTR ≥ 70% (high TTR). We 
included 1 067 participants (high TTR, N=413; low TTR, N=654) in the analysis. In unadjusted analysis, 
patients with a high TTR were older and less likely to have had strokes or receive other antiplatelet 
agents. Those patients also had lower NYHA class, better MLWHF scores, greater 6-minute walk 
distance and lower frequency of HF hospitalizations. Multivariable analysis showed that NYHA class 
III/IV (OR:0.68 [95% confidence intervals:0.49 to 0.94]), each 10-point increase in MLWHF score (i.e. 
worse health-related quality of life) (OR: 0.92 [0.86 to 0.99]), and higher number of HF hospitalization 
per year (OR:0.45 [0.30 to 0.67]) were associated with decreased likelihood of having high TTR. In HF 
patients with systolic dysfunction, NYHA class III/IV, poor health-related quality of life and a higher 
rate of HF hospitalization were independently associated with suboptimal quality of warfarin 
anticoagulation control. These results affirm the need to assess the new approaches, such as direct oral 
anticoagulants, to prevent thromboembolism in this patient population. 
Keywords: Heart Failure; Quality and Outcomes; Thrombosis; Warfarin  
Both American
1,2
 and European
3
 guidelines for the management of heart failure (HF) recommend 
anticoagulation for select HF patients, such as those with atrial fibrillation (AF) to prevent 
thromboembolism. In this setting, warfarin remains a common choice for anticoagulation, necessitating 
periodic monitoring of the international normalized ratio (INR) to adjust dosage. In patients on warfarin, 
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high quality of anticoagulation, as measured by the average time in therapeutic range (TTR), is 
associated with less thromboembolic event such as stroke or myocardial infarction.
4,5
 Previously using 
the data of patients with HF with reduced ejection fraction (HFrEF) and sinus rhythm from the Warfarin 
versus Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) trial
6
, we have demonstrated that 
patients on warfarin with high TTR is associated with improved net clinical benefit compared both with 
patients on warfarin with low TTR and patients on aspirin only.
7
 Unlike patients with AF, however, 
knowledge who tend to have a better anticoagulation among HFrEF patients is limited despite of high 
incidence of thrombosis among this population. We therefore undertook the present analysis of HFrEF 
patients enrolled in the WARCEF trial
6
 to investigate the association between HF severity and TTR. 
METHODS 
The protocol of the randomized, double-blinded WARCEF trial (http://www.ClinicalTrials.gov Trial 
Reg no. NCT00041938) has been described previously.
6
 Briefly, participants with LVEF ≤ 35% who 
were in sinus rhythm were randomized to receive warfarin or aspirin. Additional eligibility criteria 
included age ≥ 18 years old, having no contraindications to warfarin, having a modified Rankin score of 
≤ 4, and on evidence-based heart failure medications (beta-blocker, angiotensin-converting enzyme 
[ACE] inhibitor, or angiotensin II receptor blockers [ARB], or hydralazine and nitrates). Participants 
were excluded if they had a clear indication for warfarin or aspirin, or if they had a condition that 
conferred a high risk of cardiac embolism. A total of 2,305 participants (warfarin arm, N=1,142; aspirin 
arm, N=1,163) were randomized from 168 centers in 11 countries from October 2002 to January 2010. 
The mean follow-up time was 3.5 ± 1.8 years. Institutional Review Boards at the coordinating centers 
for all sites approved the study, and all participants provided informed consent.  
For this analysis, we included participants from the warfarin arm of the WARCEF trial only. Of these, 
75 were excluded because they either had follow-up time less than six weeks or had a continuous 
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interruption of warfarin therapy after six weeks and therefore had missing TTR throughout the study. 
The final study sample thus included 1,067 participants. 
 Assessment of TTR in WARCEF participants was described previously
6,7
. Briefly, we assumed that 
any change between two consecutive INR measurements takes place linearly over a 5-day period. For 
the time period between two consecutive INR measurements, we imputed INR backwards using the INR 
value of the second measurement until five days after the first measurement. Then we imputed the first 
five days using linear interpolation of these two INR values.
8
 As an example, if the measured INR was 
1.0 on day 1 and 2.0 on day 10, the imputed INRs are 1.2, 1.4, 1.6, and 1.8 on day 2, 3, 4, and 5, 
respectively, and are 2.0 on days 6 to 9. A six-weeks initial titration phase is allowed. The TTR for each 
patient is the patient’s percentage of time on warfarin for which the patient was in therapeutic range 
(INR of 2 to 3.5) from the 7th week to the end of follow-up. Based on the previous literature
9
, final TTR 
≥ 70% were defined as the high TTR group and the rest as the low TTR group.  
 For this analysis, we considered the rate of HF hospitalizations per year as a marker of HF severity. 
An independent end-point adjudication committee adjudicated all outcomes and major adverse events in 
WARCEF, and HF hospitalizations were defined as hospital admission for HF or hospitalization for 
which HF was a major contributing factor for admission and which met all of the following criteria:1) 
signs and symptoms of HF on admission; 2) admission to the hospital for at least 24 hours, excluding 
time in an emergency room or observation unit; and 3) the use of intravenous diuretic, vasodilator, or 
inotropic therapy for the purposes of treating HF. We also considered New York Heart Association 
(NYHA) functional class as a measure of severity of HF symptoms and exercise capacity, as well as 
health-related quality of life measured by the Minnesota Living With Heart Failure (MLWHF) 
questionnaire, which has been shown to be a powerful predictor of morbidity and mortality among HF 
patients.
10
 MLWHF score was categorized in three groups (MLWHF score: 0–23, good; 24–45, 
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moderate; 45–105, poor quality of life)11. Finally, we measured exercise capacity of the participants 
quantitatively by the distance walked in six minutes. 
 To address all possible associations between clinical variables and high TTR, we considered all 
baseline characteristics obtained in the trial (Table 1). Briefly, for independent variables, we included 
demographic characteristics such as age, sex, race/ethnicity, education, and clinical characteristics 
including vitals (height, weight, body mass index, systolic and diastolic blood pressure, pulse rate), life 
style risk factors (smoking status, alcohol consumption), comorbidities and past medical history, 
medications, laboratory data, and LV ejection fraction. The definitions of each variable were detailed 
elsewhere
6
. 
 Data analysis was conducted SAS software version 9.4 [SAS Institute Inc., Cary, NC]. Participants’ 
characteristics are presented as the mean ± standard deviation (SD) for continuous variables and as a 
proportion for categorical variables. These values were compared between high TTR group and low 
TTR group using a two-sample t-test for continuous variables and χ2 test for categorical variables. 
Logistic regression models were used to assess the association between the high TTR and 
clinical/demographic variables. We also used restricted cubic splines in univariable models to check the 
potential nonlinear association between high TTR and each variable. In all models, the outcome was 
high TTR. The final multivariable model was built using forward-backward stepwise selection with 
entry and removal criteria of p = 0.05. Missing values of baseline variables were imputed using means 
for continuous variables and modal values for categorical variables. For all statistical analyses, a two-
tailed P < 0.05 was considered significant. 
RESULTS 
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For the 1,067 WARCEF participants on warfarin therapy included in this analysis, the mean TTR was 
62.6%. INR values were below 2.0 for 27.1% of the total treatment time and above 3.5 for 10.3% of the 
total treatment time. The mean INR value during treatment was 2.5 ± 0.95.  
Table 1 presents the descriptive data categorized by TTR ≥ 70% or not. The participants with high 
TTR were older, more likely to have a history of myocardial infarction, worse kidney function, higher 
pulse, better MLWHF score, longer distance walked in 6 minutes, and fewer HF hospitalization. These 
participants were less likely to have hypertension, history of stroke or transient ischemic attack, and to 
be on other antiplatelet agents.  
Relations between HF severity and TTR are depicted in Figure 1. Those with higher rate of HF 
hospitalization were likely to have low TTR: the median TTR of 0, 0–1, and >1 HF hospitalization per 
year was 64.9, interquartile range (IQR) [42.7–80.3], 58.0 [31.0–73.3], and 35.2 [8.1–58.8], p < 0.001, 
respectively (Figure 1A). For NYHA class, the median TTR among participants with NYHA I/II and 
III/IV were 65.8, IQR [42.7–80.3] and 56.4 [33.1–73.7], p < 0.001, respectively (Figure 1B). Higher 
health-related quality of life was associated with higher TTR: the median TTR of good, moderate, poor 
quality of life was 68.8, IQR [48.7–82.7], 63.3 [44.5–77.4], and 52.0 [21.1–73.9], p < 0.001, 
respectively (Figure 1C).  
In the multivariable model after the stepwise selection, we found a higher number of HF 
hospitalization per year, NYHA class III/IV, and each 10-point increase in MLWHF score were 
independently associated with decreased likelihood of having high TTR ≥ 70%. Other significant 
predictors of high TTR were location, older age, race/ethnicity, greater weight, smoking status and other 
antiplatelet medications (as detailed in Table 2). 
DISCUSSION 
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The present study demonstrated for the first time that markers of HF severity are associated with TTR. 
In our analysis of patients with HFrEF and sinus rhythm enrolled in WARCEF, HF severity were 
associated with the quality of anticoagulation independent of other important clinical factors. Our results 
suggest that for patients with HF being considered for warfarin therapy, those with more advanced HF 
may have more difficulty in achieving high quality of anticoagulation.  
Although warfarin titration in HF patients is known to be challenging
12,13
, there are several potential 
mechanisms for why HF severity may be an important risk factor for suboptimal TTR. It is possible that 
patients with more severe HF may have poorer adherence to taking warfarin or to follow-ups for INR.
14
 
It is also possible that fluctuating volume status with intermittent volume overload from HF can affect 
intestinal absorption
15
 and metabolism of warfarin. For example, HF induced malabsorption of vitamin 
K or insufficient intake of vitamin K may predispose patients taking warfarin to INR elevations.
16
 
Likewise, liver impairment due to congestive HF
17
 may interact warfarin response because the hepatic 
enzyme is responsible for oxidative metabolism of warfarin
18
, while also leading to insufficient 
production of clotting factors and platelets. There may also be an interaction between cardiovascular 
comorbidities and genetic determinants of warfarin metabolism, such as CYP2C9 and VKORC1 
mutations.
19-21
 Further research is needed to clarify these mechanisms. 
Previous studies have examined the factors affecting quality of warfarin anticoagulation in patients 
with AF
22-26
 and identified that the patients with HF were less likely to achieve target INR range.
22,24
 For 
instance, the SAMe-TT2R2
22
 score was developed from the cohort of the AFFIRM (AF Follow-up 
Investigation of Rhythm Management) trial and externally validated in prospectively recruited 286 
patients. They identified following factors were associated with suboptimal warfarin anticoagulation: 
female, less than 60 years of age, history of comorbidities such as hypertension, diabetes, coronary 
artery disease, peripheral arterial disease, congestive HF, stroke, pulmonary disease, liver or renal 
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disease, medications which have interaction with warfarin such as amiodarone, tobacco use within 2 
years and non-white race. Although mixed results have been observed in other studies
22-26
, younger age, 
female, and non-white race/ethnicity were consistently associated with unfavorable INR control. Our 
findings are broadly similar. In our analysis, we confirmed that younger age and non-Hispanic black 
race/ethnicity were associated with low TTR. Although the specific mechanism of association between 
older age and warfarin control is unknown, a possible explanation is that older patients tend to have 
higher medication adherence than younger patients.
27
 In contrast to previous studies, female sex was not 
independently associated with quality of anticoagulation control in our analysis, possibly due to the 
modest number of female participants in the WARCEF trial (approximately 20%). 
 For specific HF patients, such as those with AF or with a high risk for cardioembolism, both 
American and European current guidelines recommend anticoagulation to prevent thromboembolism.
1-3
 
Although not directly addressed by our analysis, we suspect that predictors of suboptimal TTR would be 
similar to patients with HFrEF who have other indications for anticoagulation. Identifying such patients 
may be useful to determine the optimal target population for the use of direct oral anticoagulants 
(DOACs) as DOACs have favorable risk-benefit profiles.
28
 Given that optimal warfarin anticoagulation 
may be difficult to achieve especially in patients with more severe HF, our results also affirms the need 
to assess the effect of DOACs in this population, such as through the ongoing COMMANDER HF trial, 
which seeks to assess the effectiveness and safety of rivaroxaban in reducing the risk of death, 
myocardial infarction or stroke in participants with HF and coronary artery disease following an episode 
of decompensated HF (https://ClinicalTrials.gov/show/NCT01877915).  
 There are several limitations to address. First, the cross-sectional design of our study limits causal 
inference for the relationship between the quality of anticoagulation and HF severity. Second, we could 
not exclude the possibility that a hereditary predisposition contributed to warfarin resistance because we 
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did not collect the information about genetic polymorphisms. However, the previous randomized trial 
has shown that baseline genetic testing on sensitivity to warfarin does not affect clinically important 
outcomes
29
. Third, the generalizability of our study might be limited because the WARCEF population 
included only HFrEF patients in sinus rhythm. While we expect similar mechanisms to be at play for HF 
patients in general, generalizability to HFrEF patients with AF will need to be validated in future studies. 
Fourth, the standard of care for HF during the WARCEF trial may differ from contemporary practice. It 
is reassuring that background pharmacological therapy for WARCEF participants are largely similar to 
the current era though angiotensin receptor-neprilysin inhibitor was not yet available as a treatment 
option, with >98%, 90%, 60% of patients receiving an ACE inhibitor or ARB, a beta-blocker, or a 
mineralocorticoid receptor antagonist, respectively. However, potential confounding may remain from 
unmeasured differences in how heart failure or anticoagulation were managed during the WARCEF era 
compared to the current one. Fifth, we did not measure the severity of HF by using existing risk scores 
such the MAGGIC Risk Score
30
, as we did not capture the data elements necessary to calculate such 
scores. 
 In conclusion, a higher rate of HF hospitalizations, NYHA class III/IV, and poor quality of life were 
independently associated with suboptimal warfarin anticoagulation control among HF patients with 
reduced ejection fraction. These results affirm the need to assess the new approaches, such as direct oral 
anticoagulants, to prevent thromboembolism in this patient population. 
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Figure legends 
Figure 1.  
Heart Failure severity and quality of warfarin anticoagulation  
A. Average number of HF hospitalization per year B. NYHA class C. Health-related quality of life 
HF, heart failure; TTR, time in therapeutic range; NYHA, New York Heart Association; MLWHF score, 
Minnesota Living with Heart Failure score. 
Quality of warfarin anticoagulation was measured by measured by the average time in therapeutic range 
(TTR). Health-related quality of life was measured by Minnesota Living with Heart Failure (MLWHF) 
score. MLWHF score was categorized in three groups (MLWHF score: 0–23, good; 24–45, moderate; 
45–105, poor health-related quality of life).  
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Table 1. Participants characteristics by time in therapeutic range  
 
Variables 
Time in therapeutic 
range ≥ 70% 
(n=413) 
Time in therapeutic 
range < 70% 
(n=654) p-value 
Location   <0.001 
Argentina 16/413 (3.9%) 23/654 (3.5%) . 
Europe 226/413 (54.7%) 271/654 (41.4%) . 
North America 171/413 (41.4%) 360/654 (55.0%) . 
Age (years) 62.8±11.1 59.4±11.7 <0.001 
Men 337/413 (81.6%) 509/654 (77.8%) 0.139 
Non-Hispanic white 356/413 (86.2%) 453/654 (69.3%) <0.001 
Non-Hispanic black 21/413 (5.1%) 128/654 (19.6%) . 
Hispanic 27/413 (6.5%) 54/654 (8.3%) . 
Other 9/413 (2.2%) 19/654 (2.9%) . 
Educational level   0.281 
< High school 187/413 (45.3%) 268/654 (41.0%) . 
High school + 165/413 (40.0%) 293/654 (44.8%) . 
College + 61/413 (14.8%) 93/654 (14.2%) . 
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Height (cm) 172.0±9.0 171.3±9.4 0.254 
Weight (kg) 86.1±19.0 85.5±20.3 0.658 
Systolic blood pressure (mmHg) 123.2±17.9 124.2±20.0 0.398 
Diastolic blood pressure (mmHg) 73.3±11.3 74.4±11.7 0.133 
Pulse (beats/min) 70.6±11.2 72.7±11.6 0.003 
Body-mass index (kg/m
2
) 29.0±5.5 29.0±6.3 0.891 
Smoking status   0.001 
Current  59/412 (14.3%) 147/653 (22.5%) . 
Former 234/412 (56.8%) 304/653 (46.6%) . 
Never 119/412 (28.9%) 202/653 (30.9%) . 
Alcohol Consumption (oz/day)   0.110 
Current, >2 106/413 (25.7%) 156/654 (23.9%) . 
Previous, >2 76/413 (18.4%) 156/654 (23.9%) . 
Never 231/413 (55.9%) 342/654 (52.3%) . 
Hypertension 215/397 (54.2%) 405/634 (63.9%) 0.002 
Prior stroke or TIA 42/412 (10.2%) 98/653 (15.0%) 0.024 
Atrial Fibrillation 15/412 (3.6%) 21/654 (3.2%) 0.705 
Myocardial Infarction 222/412 (53.9%) 291/653 (44.6%) 0.003 
Diabetes Mellitus 131/412 (31.8%) 216/653 (33.1%) 0.664 
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Ischemic Cardiomyopathy 193/412 (46.8%) 262/653 (40.1%) 0.031 
Peripheral Vascular Disease 47/413 (11.4%) 83/654 (12.7%) 0.524 
Living with ICD 73/412 (17.7%) 119/654 (18.2%) 0.843 
Hematocrit (%) 41.9±4.1 41.6±4.7 0.330 
eGFR (mL/min/1.73 m²) 66.3±19.9 69.3±21.3 0.018 
Left ventricular ejection fraction (%) 24.8±7.2 24.5±7.7 0.525 
NYHA class   0.002 
I 64/411 (15.6%) 76/653 (11.6%) . 
II 245/411 (59.6%) 342/653 (52.4%) . 
III 98/411 (23.8%) 224/653 (34.3%) . 
IV 4/411 (1.0%) 11/653 (1.7%) . 
Baseline MLWHF score 29.0±21.2 37.7±24.8 <0.001 
Distance covered on 6-minute walk 
(meters) 
362.9±145.2 334.2±139.4 0.002 
Average number of HF hospitalization per 
year 
0.2±0.7 0.6±1.4 <0.001 
Aspirin 220/388 (56.7%) 353/596 (59.2%) 0.432 
Other antiplatelet agent 6/173 (3.5%) 23/228 (10.1%) 0.011 
ACE Inhibitor 344/412 (83.5%) 556/652 (85.3%) 0.433 
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ARB 72/412 (17.5%) 100/652 (15.3%) 0.356 
Beta-blocker 374/412 (90.8%) 588/652 (90.2%) 0.749 
Calcium-channel blocker 33/412 (8.0%) 58/652 (8.9%) 0.615 
Diuretic 322/412 (78.2%) 542/652 (83.1%) 0.043 
Statin 264/322 (82.0%) 385/456 (84.4%) 0.367 
Aldosterone blocker 148/252 (58.7%) 241/381 (63.3%) 0.252 
TIA, temporary ischemic attack; ICD, implantable cardioverter–defibrillator; ACE, angiotensin-
converting enzyme; ARB, angiotensin II receptor blocker; NYHA, New York Heart 
Association; MLWHF, Minnesota Living With Heart Failure; HF, heart failure. 
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Table 2. Association between time in therapeutic range ≥ 70 % and clinical factors 
 
Variables 
For a 
change of 
Univariable model Multivariable model 
OR (95% CI) p-value OR (95% CI) p-value 
Location      
 Argentina  reference < 0.001 reference 0.007 
 Europe  1.2 (0.62,2.32)  0.82 
(0.30,2.25) 
 
 North America  0.68 
(0.35,1.33) 
 0.52 
(0.20,1.37) 
 
Age (years)  10 1.30 
(1.16,1.45) 
< 0.001 1.28 (1.12, 
1.46) 
< 0.001 
Men  1.26 
(0.93,1.72) 
0.139   
Non-Hispanic white  reference < 0.001 reference < 0.001 
Hispanic  0.64 
(0.39,1.03) 
 0.6 (0.29,1.25)  
Non-Hispanic black  0.21 
(0.13,0.34) 
 0.3 (0.18,0.51)  
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Other  0.6 (0.27,1.35)  0.6 (0.26,1.40)  
Educational level      
 < High school  reference 0.282 reference  
 High school +  0.81 
(0.62,1.05) 
   
 College +  0.94 
(0.65,1.37) 
   
Height (cm)   1.01 
(0.99,1.02) 
0.254   
Weight (kg, Linear Spline)       
 < 72.7  1.43 
(1.08,1.89) 
0.041   
 > 72.7  0.95 
(0.88,1.03) 
   
Weight (kg)  10 1.01 
(0.95,1.08) 
0.657 
1.12 
(1.04,1.21) 
0.004 
Systolic BP (mmHg)  10 0.97 
(0.91,1.03) 
0.397 
0.91 (0.85, 
0.98) 
0.015 
Diastolic BP (mmHg)  10 0.92 
(0.83,1.03) 
0.133   
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Pulse (beats/minutes)  0.98 
(0.97,0.99) 
0.003   
Body-mass index (kg/m
2
, Linear 
Spline) 
 
    
 < 25.1 1.15 
(1.04,1.27) 
0.019   
 > 25.1 0.98 
(0.95,1.00) 
.   
Body-mass index (kg/m
2
)  1.00 
(0.98,1.02) 
0.892   
Smoking status      
 Never  reference 0.001 reference 0.013 
 Current  0.68 
(0.47,0.99) 
 
0.77 
(0.51,1.16) 
 
 Former  1.31 
(0.99,1.74) 
 
1.32 
(0.97,1.79) 
 
Alcohol consumption (oz/day)      
 Never  reference 0.111   
 Current, >2  1.01 
(0.75,1.36) 
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 Previous, >2  
0.72 
(0.52,0.99) 
   
Hypertension  0.68 
(0.53,0.88) 
0.003   
Prior stroke or TIA  0.64 
(0.44,0.94) 
0.024   
Atrial Fibrillation  1.14 
(0.58,2.23) 
0.711   
Myocardial Infarction  1.45 
(1.13,1.86) 
0.003   
Diabetes Mellitus  0.94 
(0.72,1.23) 
0.657   
Ischemic Cardiomyopathy  1.31 
(1.02,1.68) 
0.032   
Peripheral Vascular Disease  0.88 
(0.60,1.29) 
0.524   
Living with ICD 
 0.97 
(0.70,1.33) 
0.829   
Hematocrit (%, Linear Spline)       
 < 39.2 1.12 
(1.03,1.21) 
0.030   
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 > 39.2 0.97 
(0.93,1.02) 
   
Hematocrit (%)  1.01 
(0.99,1.04) 
0.328   
eGFR (mL/min/1.73 m
2
) 
 
0.99 
(0.99,1.00) 
0.019   
LV ejection fraction (%)   1.01 
(0.99,1.02) 
0.525   
NYHA class III or IV  0.58 
(0.44,0.77) 
< 0.001 
0.68 
(0.49,0.94) 
0.020 
Baseline MLWHF score (points) 10 0.85 
(0.80,0.90) 
< 0.001 
0.92 (0.86, 
0.99) 
0.017 
Distance covered on 6-minute walk 
(meters)  
30 1.04 
(1.02,1.07) 
0.002   
Average number of HF hospitalization 
per year 
 0.72 
(0.61,0.84) 
< 0.001 
0.45 
(0.30,0.67) 
< 0.001 
Aspirin  0.86 
(0.67,1.11) 
0.250   
Other antiplatelet agent  
0.4 (0.16,1.00) 0.050 
0.33 
(0.13,0.87) 
0.025 
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ACE Inhibitor  0.87 
(0.62,1.22) 
0.431   
ARB  1.17 
(0.84,1.63) 
0.354   
Beta-blocker  1.07 
(0.70,1.63) 
0.752   
Calcium-channel blocker  0.89 
(0.57,1.39) 
0.617   
Diuretic  0.73 
(0.53,0.99) 
0.043   
Statin  0.75 
(0.51,1.08) 
0.121   
Aldosterone blocker  0.81 
(0.61,1.08) 
0.153   
OR, odds ratio; CI, confidence interval; TIA, temporary ischemic attack; ICD, implantable cardioverter–
defibrillator; ACE, angiotensin-converting enzyme; ARB, angiotensin II receptor blocker; eGFR, 
estimated glomerular filtration rate; LV, left ventricular; BP, blood pressure; NYHA, New York Heart 
Association; MLWHF, Minnesota Living With Heart Failure; HF, heart failure.  
The final multivariable model was built using forward-backward stepwise selection with entry and 
removal criteria of p=0.05. 
 
